Febbo Phillip G. 4

What Happened

• Phillip G. Febbo, Veracyte’s Chief Scientific & Medical Officer, was granted two restricted stock unit (RSU) awards on March 6, 2026 totaling 36,181 RSUs: 29,603 RSUs and 6,578 RSUs. Both awards were grants (transaction code A) with a $0 acquisition price at grant (standard for RSU awards).

Key Details

• Transaction date: March 6, 2026; Form 4 filed March 10, 2026 (appears timely under the two-business-day rule).
• Award amounts and price: 29,603 RSUs @ $0.00 and 6,578 RSUs @ $0.00 (total 36,181 RSUs).
• Shares owned after transaction: not disclosed in the provided filing excerpt.
• Footnotes/vesting:
  • F1: The 29,603 RSUs vest 25% on March 2, 2027, then 1/16 of the grant each quarter thereafter, subject to continuing employment.
  • F2: The 6,578 RSUs vest in full on the first anniversary of the grant, subject to continuing employment.
• Transaction type: Award/grant (not a market purchase or sale).

Context

• RSU grants are compensation, not immediate purchases or sales; they convert to shares only as they vest and typically depend on continued employment. The economic value will depend on Veracyte’s stock price at vesting. Awards like these are common executive compensation and do not by themselves signal a current buy/sell decision.